Evidence map›Paper›PMID 40756159›Full record

ArticleEuropean urology open science2025

Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials.

Bhavna Oza, Eleni Frangou, Tim Eisen, Grant D Stewart, Axel Bex, David Harrison, Mahesh K B Parmar, Ruth Langley, Duncan Gilbert, Angela Meade

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bhavna OzaMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
Eleni FrangouMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
Tim EisenDepartment of Oncology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
Grant D StewartDepartment of Surgery, Addenbrooke's Hospital, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
Axel BexUCL Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust, London, UK.
David HarrisonSchool of Medicine, University of St Andrews, St Andrews, UK.
Mahesh K B ParmarMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
Ruth LangleyMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
Duncan GilbertMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
Angela MeadeMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: Outcomes after nephrectomy for intermediate- and high-risk renal cell carcinoma (RCC) according to histological subtype are poorly characterised. This study aims to determine the value of RCC histology in predicting survival and to inform on surveillance strategies in relation to patterns of first recurrence. Methods: We pooled data from phase 3 trials: SORCE ( Key findings and limitations: Patients with pRCC and ccRCC had similar overall survival (log-rank Conclusions and clinical implications: Patients with intermediate and high-risk pRCC relapse earlier than those with ccRCC. Papillary RCC and sRCC first recurring in the abdomen exhibit poor prognosis, warranting consideration of additional abdominal imaging to enhance early relapse detection. ChRCC exhibits favourable prognosis and could avoid image-based surveillance until year 2. Patient summary: This study evaluates pooled data from large phase 3 trials to precisely delineate relapse patterns for patients with intermediate- and high-risk cell renal cell carcinoma (RCC) according to their histology. The site and timing of first relapse provide useful information to support histology-specific RCC surveillance after nephrectomy. Development of genetic and molecular signatures corresponding to relapses at poor prognosis sites for each histology will individualise follow-up and is the next step.

Indexed as

ASSUREChromophobeClear cellPapillaryRecurrence patternsRenal cell carcinomaSarcomatoidSORCE

Identifiers

PMID40756159
PMCPMC12314385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.